GCM
GILD icon

Genus Capital Management’s Gilead Sciences GILD Stock Holding History

Genus Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-191,100
Closed -$17.7M – 257
2024
Q4 		$17.7M Buy
191,100
+112,460
+143% +$10.1M 2.4% 3
2024
Q3 		$6.59M Buy
+78,640
New +$6M 0.86% 38
2024
Q1 		– Sell
-108,065
Closed -$8.75M – 278
2023
Q4 		$8.75M Buy
+108,065
New +$8.41M 1.28% 22

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Genus Capital Management's GILD Position: Q1 2026 in Review

Genus Capital Management reduced its Gilead Sciences (GILD) stake by 12% in Q1 2026, selling an estimated $2.34M and leaving 119,280 shares worth $16.6M. The position accounts for 1.91% of the portfolio, ranked #8.

Genus Capital Management first reported a position in GILD in Q2 2023 and has held it in 7 quarters since. The position peaked at $20.6M in Q1 2025. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Genus Capital Management held 119,280 shares of Gilead Sciences worth $16.6M as of Q1 2026.
  • Genus Capital Management sold 16,706 Gilead Sciences shares in Q1 2026, an estimated $2.34M.
  • Gilead Sciences made up 1.91% of Genus Capital Management's portfolio in Q1 2026, its #8 holding.
  • Genus Capital Management first reported a position in Gilead Sciences in Q2 2023 and has held it in 7 quarters since.
  • Genus Capital Management's Gilead Sciences position peaked at $20.6M in Q1 2025.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Genus Capital Management's 13F filing for Q1 2026, filed 4 May 2026.